Kabeya H, Ohashi K, Ohishi K, Sugimoto C, Amanuma H, Onuma M
Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
Vaccine. 1996 Aug;14(12):1118-22. doi: 10.1016/0264-410x(96)00047-3.
Protective effects of the gp51 of bovine leukaemia virus (BLV) expressed by a recombinant baculovirus (rgp51) and synthetic multiple antigenic peptides (MAP) of T-helper, T-cytotoxic, and B-cell epitopes of gp51 were investigated against BLV challenge. Two and three sheep were immunized with rgp51 and a mixture of peptides with Freund's complete adjuvant, respectively. BLV was detected from all the immunized sheep at 2 weeks and showed peak levels at 4 weeks after the challenge. However, in two sheep immunized with the mixed peptides, the titer of BLV gradually decreased and one sheep eliminated BLV completely at 28 weeks after the challenge. These two sheep showed higher lymphocyte proliferative responses against the immunized peptides than the other sheep. One of the sheep also showed the specific cytotoxic lymphocyte activity against the BLV gp51-expressing target in vitro. These results suggest the possibility of the peptide vaccine for elimination of BLV in carrier animals in vivo.
研究了重组杆状病毒表达的牛白血病病毒（BLV）的gp51（rgp51）以及gp51的T辅助、T细胞毒性和B细胞表位的合成多抗原肽（MAP）对BLV攻击的保护作用。分别用rgp51和肽混合物与弗氏完全佐剂免疫2只和3只绵羊。在攻击后2周从所有免疫绵羊中检测到BLV，并在攻击后4周达到峰值水平。然而，在用混合肽免疫的2只绵羊中，BLV滴度逐渐下降，其中1只绵羊在攻击后28周完全清除了BLV。这2只绵羊对免疫肽的淋巴细胞增殖反应高于其他绵羊。其中1只绵羊在体外还表现出针对表达BLV gp51的靶标的特异性细胞毒性淋巴细胞活性。这些结果提示了肽疫苗在体内消除携带动物中BLV的可能性。
